MENU

The Rapid Development of COVID-19 Vaccines

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Professor of Medicine, University of Alabama at Birmingham Director, Alabama Vaccine Research Clinic (AVRC)
    Biography

      Dr. Goepfert holds the Edward W. Hook III, MD Endowed Professorship in Infectious Diseases in the Department of Medicine at the University of Alabama at Birmingham (UAB) and the Director of the Alabama Vaccine Research Clinic (AVRC).  His laboratory research interests are focused on T cell immunology and vaccine design.  He has recently begun analyzing T cell responses to COVID-19 using samples obtained from patients at UAB.  Dr. Goepfert's clinical research interest is centered on the testing of preventative vaccines through the AVRC which has previously focused on HIV but now is studying COVID-19 vaccines as well. He has also overseen vaccines trials designed to prevent anthrax, HPV, HBV, influenza, and small pox.  He is authored over 140 peer-reviewed papers largely focused on immunology and vaccines.


    Abstract

    Vaccines to prevent COVID-19 were developed within 1 year after the identification of SARS-CoV-2 as the causative virus. There are now 3 vaccines that are FDA approved via Emergency Use Authorization. This talk will highlight how one of those vaccines was developed. It will focus on how rapid development of the vaccines were attained while still testing them rigorously for safety. It will also show how these vaccines work as well as present safety, efficacy, and immune data. It will end with a brief discussion on which vaccines have been developed and shown to be effective in preventing COVID-19 across the world.

    Learning Objectives: 

    1. Understand how mRNA vaccines work

    2. Understand how COVID-19 vaccines were approved so rapidly without impacting their safety


    Show Resources
    You May Also Like
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    C.E. CREDITS
    Antibody tests are important tools to assess the efficacy of vaccine candidates and to derive suitable vaccination modalities. High specificity and sensitivity are of great importance for th...
    Loading Comments...
    Show Resources
    Attendees
    • See more